Kennedy’s Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Kennedy's disease, called bulbospinal
muscular atrophy (BSMA), is a rare genetic disorder following an X-linked
recessive inheritance pattern characterized by the degeneration of motor
neurons leading to muscle wasting in the proximal and bulbar regions. BSMA is
caused by an unstable expansion of a CAG triplet repeat (40-62 repeats) in exon
1 of the androgen receptor (AR) gene located on chromosome Xq11-12. The onset
of symptoms typically occurs between the ages of 30 and 60 years, and initial
clinical manifestations may include tremors, muscle cramps, twitching, fatigue,
and slurred speech. With disease progression, patients may experience weakness
and wasting of the limb and bulbar muscles, resulting in dysarthria, dysphonia,
hanging jaw, tongue wasting, chewing difficulty, and impaired mobility. The
disease may be misdiagnosed initially as hereditary spastic paraplegia,
spinocerebellar ataxia, other motor neuron diseases, myopathies, neuropathies,
or cervical spondylosis. The progression of BSMA is slow, with only one-third
of patients requiring a wheelchair 20 years after diagnosis. The prognosis for
BSMA is generally favorable, with only a slight decrease in life expectancy.
·
The estimated incidence of Kennedy's disease
in the USA is approximately 1 case in 40,000 men.
Thelansis’s “Kennedy’s Disease Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Kennedy’s Disease treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Kennedy’s Disease across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Kennedy’s Disease Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment